Skip to main content

Bodycad

SoftwareQuebec City, Quebec, CanadaFounded 2011· One of 350 Software companies tracked by AMPulse

Develops proprietary Personalized Restoration™ Software and vertically integrated 3D printing services for patient-specific orthopedic implants and instruments, reducing custom implant lead times from months to 21 days.

CEO / Founder
Geoffroy Rivet-Sabourin
Team Size
51-200
Stage
Active
Total Funding
$5.2M
Latest Round
Series A
Key Investors
Desjardins Capital; Fonds de solidarité FTQ; Anges Québec Capital; Anges Québec

Technology & Products

Key Products

Personalized Restoration™ Software, personalized orthopedic implants and instruments, Personalized Unicompartmental Knee System

Technological Advantage

Proprietary Personalized Restoration™ Software with automated segmentation algorithms and 20+ years of anthropometric data research, protected by trade secrets and regulatory clearances (FDA 510(k), Health Canada).

Differentiation

Value Proposition

Reduces custom orthopedic implant production time by 75% (from months to 21 days) while improving surgical precision and patient outcomes through truly personalized designs, enabling on-demand manufacturing of patient-specific solutions.

How They Differentiate

3x faster custom implant production (21 days vs. industry standard 2-3 months) with fully integrated software-to-manufacturing workflow, unlike competitors who often rely on third-party printing or generic design tools.

Market & Competition

Target Customers

Orthopedic surgeons, hospitals, healthcare institutions

Industry Verticals

Medical; Healthcare

Competitors

TechMed 3D; 3D Systems Corporation; Zimmer Biomet

Growth & Milestones

Growth Metrics

Employee count grew 45% last year; revenue reported as $16.2M annually.

Major Milestones

Founded in 2011 by Jean Robichaud; FDA 510(k) clearance for Fine Osteotomy™ (2025); Health Canada approval for BC Fine Osteotomy™; Exclusive U.S. distribution agreement with Exactech (2020); First patient use of unicompartmental knee system

Notable Customers

Exactech; Hospital Innovations

Why this company matters

BodyCAD develops proprietary Personalized Restoration Software and operates a vertically integrated manufacturing facility that combines CAD/CAM design tools with in-house metal and polymer 3D printing and CNC machining. The company targets orthopedic surgeons and hospitals with patient-specific implants and instruments, reducing lead times from the industry standard of two to three months down to 21 days. Its Personalized Unicompartmental Knee System is one example of a product designed for on-demand, patient-specific production.

The company's technological advantage rests on its proprietary software, which includes automated segmentation algorithms and draws on over 20 years of anthropometric data research. BodyCAD holds FDA 510(k) clearance for its Fine Osteotomy system and Health Canada approval for the BC Fine Osteotomy system. Its IP is protected primarily through trade secrets and regulatory clearances rather than a large patent portfolio, though it does hold a patent on drill-stop cutting technology.

BodyCAD serves the medical and healthcare verticals, with notable distribution partners including Exactech for exclusive U.S. distribution of the Reflex Uni knee system, Hospital Innovations, and OrthoGrow for EU distribution. The company has also collaborated with EOS on surgical drilling templates. Its competitors include TechMed 3D, 3D Systems Corporation, and Zimmer Biomet, but BodyCAD differentiates through a fully integrated software-to-manufacturing workflow that avoids reliance on third-party printing or generic design tools.

Founded in 2011 by Jean Robichaud and led by CEO Geoffroy Rivet-Sabourin, the company has raised $5.2 million from investors including Desjardins Capital, Fonds de solidarité FTQ, and Anges Québec Capital. With annual revenue reported at $16.2 million and employee growth of 45 percent in the past year, BodyCAD has established itself as a credible player in the patient-specific orthopedic implant space. An open question is whether its vertically integrated model can scale to meet broader hospital demand without sacrificing the 21-day lead time that defines its value proposition.